September 30, 2026 – Healventures

HVL Asia Healthcare Investment Fellowship

12주 실무형 헬스케어 투자·사업개발 프랙티컴 💡🌏 글로벌 바이오·헬스케어 VC 및 자문사 Heal Venture Lab(HVL)에서 12주간 멘토링 기반으로 헬스케어 투자 실무와 아시아 시장 진출 전략을 배우고

September 30, 2026 No Comments

The Future of Asian Biotech: Bridging the "Valley of Death" | AHA Q1 2026 Recap

What is the state of healthcare investment in 2026? In this special session of the Alliance of Healthcare Investors in Asia (AHA), we convene a closed-door panel of investors, operators, ...and strategics from Singapore, China, Korea, Taiwan, and the US.

The consensus is clear: Biotech is cross-border by default. We break down the shift toward early-stage innovation and how Asia is uniquely positioned to capture value where global capital has traditionally pulled back.

Key Discussion Points:
- Asset Selection: Why "strong science" is only the beginning—how to identify assets that compound in value.
- The "Valley of Death": Capitalizing on the gap in early-stage development while global markets focus on de-risked assets.
- The China-Singapore Pathway: A strategic look at originating IP in China and leveraging Singapore for global translational development.
- Navigating Cross-Border Complexity: Why regulatory and commercial success now requires a multi-geography strategy.

00:00 Introduction: The Future of Asian Biotech
35:31 Keynote: The BlueJay Therapeutics Story (Dr. Keting Chu)
1:11:21 The Funding Shift: Navigating the "Valley of Death"
1:29:46 The Scientist’s Edge: Why Science is the Only Metric
1:40:24 Strategic Corridor: Bridging China and Singapore
2:02:47 Global Regulatory Strategy: Speed vs. Market Size
2:23:13 Regional Market Access: Mutual Recognition & Work Sharing ClosingShow More

Day: September 30, 2026

HVL Asia Healthcare Investment Fellowship

The Future of Asian Biotech: Bridging the "Valley of Death" | AHA Q1 2026 Recap